[Sumatriptan nasal spray 20mg: efficacy, tolerance and quality of life in migraine patients].
The primary objective of this prospective, open, non controlled, multicenter study was to collect data on migraine patients' health related quality of life before and after treatment of their migraine attacks by sumatriptan nasal spray 20 mg over a 12 week period. The impact on health related quality of life was evaluated by the mean change from pre-treatment scores french migraine health related quality of life specific questionnaire (QVM). A total of 219 patients have been included in the study, whose migraine attacks were not usually relieved by first line therapy. A statistically significant improvement in health related quality of life (as measured by the global score and the four scores related to the four dimensions of the QVM questionnaire (functional, psychological, social and therapeutic) were observed compared to the pre-treatment score values. At the end of the treatment period, 60% of patients preferred sumatriptan nasal spray 20 mg to their usual treatment. Headache relief was reported 2 hours after administration in 66% of attacks treated by sumatriptan nasal spray 20 mg during the study period and pain free in 46% of treated attacks. The nature and incidence of adverse events were similar to these observed in previous studies performed with sumatriptan nasal spray 20 mg and no unexpected events were reported.


CONCLUSIONS
Those data suggest for the first time that the use of sumatriptan nasal spray 20 mg for the treatment of migraine attacks during a 12 week period may be associated with a significant improvement in migraine patients' quality of life. The clinical efficacy and tolerability results observed in this study are similar to those from controlled studies previously published with sumatriptan nasal spray 20 mg.
Géraud
G
G
Service de neurologie, Centre Hospitalo-Universitaire de Rangueil, Toulouse.
Valette
C
C
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000523:psychology; D009325:Nausea / Q000139:chemically induced; D011788:Quality of Life; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan